JMKX 001899
Alternative Names: JMKX-001899Latest Information Update: 26 Nov 2025
At a glance
- Originator Jemincare
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
- Research Colorectal cancer
Most Recent Events
- 21 Nov 2025 Jemincare plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, once daily), in December 2025 (NCT07242274)
- 06 Jun 2025 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (PO) (NCT06946927)
- 27 Apr 2025 Jemincare plans phase I trial in Non small cell lung cancer (Combination therapy, Metastatic disease and Late-stage disease) in China in June 2025 (PO) (NCT06946927)